Glaukos Corporation (GKOS) surged approximately 33.9% over the last 30 days, climbing from $110.78 on June 2, 2026, to $148.34 on July 2, 2026, and reaching a new 52-week high. The rally was fueled by a combination of a landmark reimbursement milestone for Epioxa, a pipeline advancement with GLK-321, and sustained commercial momentum from iDose TR.

Boston Scientific (BSX) shares fell approximately 20.3% over the last 30 days, dropping from $56.81 on May 19, 2026, to $45.29 on June 18, 2026. The quarterly decline is even steeper at roughly 36%, with the stock sliding from $71.28 in mid-March amid a broader medtech sector selloff.

NovoCure shares are down approximately 16% in premarket trading on June 18, 2026, with the stock quoted near $14.95 against a prior regular-session close of $17.85. The primary catalyst is the announcement that the company's Phase 3 TRIDENT trial in newly diagnosed glioblastoma failed to meet its primary endpoint of demonstrating a statistically significant improvement in overall survival.

Medtronic reported Q4 revenue of $9.807 billion, up 9.9% as reported and 6.6% organically, exceeding implied guidance by 90 basis points. Full-year fiscal 2026 revenue reached $36.364 billion, up 8.4% as reported and 5.8% organically, marking the highest annual revenue growth in 10 years.

Medtronic is set to report fourth-quarter and full fiscal year 2026 results on June 3, 2026. Analyst consensus estimates call for Q4 revenue near $9.62 billion and non-GAAP EPS of approximately $1.55.

BSX shares fell approximately 11.3% intraday, extending a sharp decline from the prior session close of $57.64. Primary catalyst: Persistent investor concerns over slowing growth in electrophysiology (EP) and WATCHMAN segments, following Q1 2026 earnings that included lowered full-year guidance.

Orthofix Medical Inc. (OFIX) shares fell sharply by 15.27% in today’s session. No single company-specific catalyst such as earnings or guidance updates drove the move.

BSX stock declined -12% over the past 30 days amid concerns over slowing growth in electrophysiology (EP) and WATCHMAN segments. Over the past quarter, the stock fell -27%, reflecting broader challenges including disappointing trial results and cautious guidance.

Analysts expect Q4 fiscal 2026 revenue of approximately $1.60 billion, up about 8% year-over-year. Consensus adjusted EPS estimate stands at $2.89, reflecting 5.5% growth from $2.74 in the prior-year quarter.

MDT stock declined approximately -13% over the past 30 days amid analyst price target reductions and concerns over EPS guidance cuts tied to the MiniMed diabetes unit spin-off. Over the past quarter, the stock fell around -25%, reflecting broader pressures from margin challenges, tariff impacts, and sector sentiment.

ATEC shares plunged 30.55% to close at $7.11 from the previous close of $10.23. Primary catalyst: Q1 2026 earnings miss with revenue of $192 million versus expectations of $197.5 million, driven by weakness in EOS imaging sales.

GEHC stock declined -13% over the past 30 days, primarily triggered by a 13% single-day drop following Q1 2026 earnings miss and lowered full-year profit guidance due to rising input costs. Over the past quarter, the stock fell -26%, reflecting broader pressures from supply chain disruptions, tariffs, and margin contraction in key segments like Patient Care Solutions.

Shares of INSP are plunging approximately 14.00% on Tuesday, May 5, 2026, falling from a prior close of $54.84 to approximately $47.17 — a new 52-week low — as Q1 2026 results released after Monday's market close delivered a meaningful revenue beat that was immediately overshadowed by a severe full-year 2026 revenue guidance cut from approximately $900–$920 million to $825–$875 million,

ABT stock declined approximately -14% over the past 30 days, driven primarily by a post-earnings sell-off following Q1 results and lowered full-year profit guidance due to the Exact Sciences acquisition. Over the past quarter, the stock fell around -20%, reflecting broader pressures from weaker nutrition and diagnostics segments amid a challenging respiratory season.

SYK stock declined approximately -10% over the past 30 days, primarily due to a Q1 2026 earnings miss attributed to a cyberattack disrupting operations. Over the past quarter, the stock fell around -19%, reflecting broader sector pressures and the cyber incident's impact in March.

BIO shares plunged 10.12% to $251.77 from the previous close of $280.12. The selloff followed first-quarter 2026 earnings that included a $527.1 million net loss driven by a $738.2 million investment impairment.

Analysts expect Q1 2026 revenue of $6.29 billion, a 7.3% increase from $5.9 billion in the year-ago quarter. Consensus adjusted EPS is forecasted at $2.98, up 4.9% year-over-year from $2.84.

Shares of GE HealthCare Technologies (GEHC) are down approximately 11% on Wednesday, sliding from a prior close of $68.50 to trade near $61, after reporting Q1 2026 earnings before the market open. Primary catalyst: Adjusted EPS of $0.99 missed the Wall Street consensus of $1.07 by $0.08 — the first notable quarterly miss after four consecutive beats.

Abbott reported first-quarter sales of $11.16 billion, up 7.8% on a reported basis and beating consensus estimates of approximately $11.01 billion. Adjusted diluted earnings per share (EPS) came in at $1.15, meeting analyst expectations and rising 6% year-over-year (YoY).

QDEL has declined -36% over the past 30 days, driven primarily by a weaker-than-expected flu season impacting respiratory diagnostics demand and disappointing 2026 guidance. Over the past quarter, the stock has fallen -63%, reflecting broader challenges in the diagnostics sector amid moderating infectious disease activity.